Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MindBio Therapeutics Corp. C.MBIO

MindBio Therapeutics Corp is a pioneering clinical stage biotechnology company that specializes in developing psychedelic microdosing treatments for mental health conditions. MindBio has obtained government and regulatory approvals for at-home LSD microdosing in clinical trials, making it the only organization in the world to do so.


CSE:MBIO - Post by User

Comment by Smokey1958on May 03, 2024 11:34am
28 Views
Post# 36021750

RE:RE:Where does the money come from?

RE:RE:Where does the money come from?Absolutely true, Sleepydog!

Mindbend has been at this for a little over 4 years which would explain the "current" difference in market cap. Being an American entity where 95% of their investors trade through one of the NASDAQ exchanges doesn't hurt either (10x the potential investors). As a consequence they just delisted from a Canadian exchange to cut costs etc and because of the practicality of doing so.

Having said that, I've read the research from MindMed and they are, as you say, essentially at the same point with their trials. In less time, with a titratable form of LSD, take home experimental design and some significant results, the only thing missing thus far for MBIO is exposure. When that changes ...and it should, investors will be well rewarded I expect.

If nothing else, MindMed provides a great deal of legitimacy to the research and potential benefits to mental health sufferers and shareholders of MBIO.



<< Previous
Bullboard Posts
Next >>